Fall 2021 Newsletter
Fall 2021 Newsletter
A Note from the President
It’s hard to believe that December is already here! Looking back on 2021, it was truly a stellar year for TransPharm Preclinical Solutions. Many businesses are still feeling the economic impacts of the pandemic, but TransPharm has been able to rebound thanks to our fantastic clients. We appreciate you!
TransPharm will close for winter break around 12pm EST on December 24, 2021 and we will return the morning of January 3, 2022. We wish you a happy holiday season and look forward to working with you in the new year!
Daniel Ross
President & CEO
In the Lab
New Preclinical Model: Diabetic Wound
TransPharm has now validated our dermal infection – deep wound model in mice with streptozotocin (STZ)-induced type 1 diabetes. A biopsy punch is used to create a full-thickness, 6 mm wound over the thoracic spine area on the dorsal surface, and then C. albicans is introduced to the wound to initiate a fungal infection. Test articles are administered topically and endpoints include photographs of the healing process and/or skin harvests.
Contact us today for more information or to request a free, no-obligation quote for your diabetic wound study.
Santiago R. Lopez, Ph.D.
Chief Scientific Officer